Results Presented at the American Diabetes Association’s Virtual 80th Scientific Sessions
Pfizer-funded research finds that 20 S. pneumoniae serotypes are associated with a substantial burden of pneumococcal disease globally1,2,3
NEW YORK, June 23 - Pfizer Inc. (NYSE:PFE) today announced that new data on the evolving burden of S. pneumoniae serotypes will be included as part of an online digital library created by the International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in place of its 2020 Scientific Program, which was postponed until 2021 due to the COVID-19 pandemic.
NEW YORK, June 29, 2020 -- Pfizer issued a statement today in response to the proposed #StopHateForProfit boycott of Facebook advertising properties:
Today, we announced that we will be removing all of our advertising from Facebook and Instagram for the month of July. For us, it’s clear that to live our value of Equity, demonstrating respect for all people and making it clear that any hate speech is unacceptable, we must speak up and take action.
New York, July 10, 2020 – Pfizer today issued an update on the company’s pre-clinical research efforts focused on developing a potential antiviral treatment for COVID-19. These updates are part of the company’s commitment to transparency in research findings related to COVID-19, as set forth in Pfizer’s five-point plan for the biopharmaceutical industry to tackle the disease caused by the novel coronavirus.
• EMA confirms successful application for Conditional Marketing Authorization for BNT162b2, which
Pfizer and BioNTech submitted yesterday
• In addition to submission to EMA, FDA and U.K. MHRA, the companies have also initiated additional
rolling submissions across the globe including in Australia, Canada and Japan, and plan to submit
applications to other regulatory agencies around the world
• Data from the Phase 3 clinical study demonstrated a vaccine efficacy rate for BNT162b2 of 95% against
COVID-19, with no safety concerns observed to date
Today, we were informed by the European Medicines Agency (EMA) that the agency has been subject to a cyberattack and that some documents relating to the regulatory submission for Pfizer and BioNTech’s COVID-19 vaccine candidate, BNT162b2, which has been stored on an EMA server, had been unlawfully accessed. It is important to note that no BioNTech or Pfizer systems have been breached in connection with this incident and we are unaware that any study participants have been identified through the data being accessed.
Today Pfizer announced that the first participants were dosed in the global Phase 2 multiple dose, randomized study to assesses the safety, tolerability, pharmacokinetics, and efficacy of recifercept in children with achondroplasia. Participants received a subcutaneous injection of the biologic recifercept at Antwerp University Hospital, Belgium, under the care of Professor Geert Mortier, and Hospital Vithas San José, Spain under Dr. Josep De Bergua.
New York, NY, December 17, 2020 – Pfizer Inc. (NYSE: PFE) today released the following statement to address public comments that allege there are issues in the production and distribution of the company’s COVID-19 vaccine:
New York, NY and Mainz, Germany, January 8, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies from people who have received the Pfizer-BioNTech COVID-19 vaccine effectively neutralize SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains.
New York and Mainz, Germany, January 15, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) developed a plan that will allow the scale-up of manufacturing capacities in Europe and deliver significantly more doses in the second quarter.